Viridian Therapeutics, Inc. VRDN Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -512.9%+98,506pp | -99,018.5%-17,984pp | -81,035%-73,456pp | -7,579.2%-4,888pp | |
| Net margin | -483.6%+88,904pp | -89,387.1%-13,676pp | -75,711.5%-68,382pp | -7,329.2%-4,649pp | |
| EBITDA margin | -512.3%+98,327pp | -98,839.7%-17,971pp | -80,868.8%-73,304pp | -7,564.8%-4,878pp | |
| Free cash flow margin | -390.8%+76,705pp | -77,096%-18,157pp | -58,938.9%-53,598pp | -5,340.6%-3,487pp | |
| Returns | |||||
| Return on equity | -49.2%-0.7pp | -48.5%+8.3pp | -56.8%-12.2pp | -44.6%+7.0pp | |
| Return on assets | -41.7%+2.1pp | -43.8%+7.6pp | -51.4%-10.7pp | -40.7%+6.8pp | |
| Return on invested capital | -64.8%-0.9pp | -63.9%+19.9pp | -83.8%-15.3pp | -68.6%+3.9pp | |
| Efficiency | |||||
| Asset turnover | 0.1×+0.1× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 12.6×-2.8× | 15.4×-2.8× | 18.3×+5.3× | 12.9×-1.7× | |
| Quick ratio | 12.6×-2.8× | 15.4×-2.8× | 18.3×+5.3× | 12.9×-1.7× | |
| Cash ratio | 3×+0.9× | 2.1×-1.8× | 3.9×-0.8× | 4.7×+1.6× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -74.1×+60.0× | -134.1×+57.1× | -191.2×+85.2× | -276.3×+26,300× | |
| Valuation | |||||
| Market capitalization | $2.97B+95.6% | $1.52B+32.6% | $1.15B-2.6% | $1.18B+174% | |
| Enterprise value | $2.79B+96.6% | $1.42B+33.5% | $1.06B+3.7% | $1.03B+165% | |
| Price / sales | 41.9×-4,986× | 5,028.2×+1,381× | 3,647.5×+2,984× | 663.5×+519× | |
| Price / book | 4.1×+1.9× | 2.3×-0.3× | 2.6×-0.4× | 3×+0.7× | |
| EV / sales | 39.4×-4,667× | 4,706.8×+1,317× | 3,390.2×+2,811× | 579.3×+448× | |
| Free cash flow yield | -9.3%+6.0pp | -15.3%+0.8pp | -16.2%-8.1pp | -8%+4.7pp | |
| Earnings yield | -11.5%+6.2pp | -17.8%+3.0pp | -20.8%-9.7pp | -11%+7.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Viridian Therapeutics, Inc. (VRDN) runs a 36.3% gross margin and a -543.9% operating margin, with a -508.5% net margin.
- Where do Viridian Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Viridian Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.